Resource Library

Creating demand for the Dapivirine vaginal ring

This presentation outlines lessons learned from ring clinical trials and oral PrEP programs in Kenya, South Africa, Uganda, and Zimbabwe that can be applied to the development of demand creation strategies.

Demand Creation/Marketing

HOPE Protocol Team Meeting Lessons Learned from PrEP Rollout for the Dapivirine Ring

This presentation outlines lessons from oral PrEP demonstration projects that could be applied to the rollout of the dapivirine vaginal ring as well as plans for ring introduction.

Research

DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF

In the DISCOVER study, F/TAF oral PrEP (Descovy) was statistically noninferior to F/TDF oral PrEP (Truvada). However, there were numerically 53% fewer HIV infections in the F/TAF arm vs. F/TDF . This study explores HIV risk, STIs, adherence, and pharmacokinetic data to evaluate this imbalance.

Research

Descovy for PrEP

The U.S. Food and Drug Administration has reported that they have approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) who at at risk of acquiring HIV.

Normative Guidance/Policies

Safety, Adherence and HIV-1 Seroconversion in DREAM – An Open-label Dapivirine Vaginal Ring Trial

The Ring Study, a phase 3 trial in 1959 sexually active women (randomised 2:1), showed a favourable safety profile and a 31% HIV-1 infection risk reduction for a vaginal ring containing 25 mg of dapivirine, compared with a placebo ring. This article features a report on the DREAM study, which aimed to evaluate safety, adherence,…

Research

IAS 2021 Satellite Session: Bringing the Dual Prevention Pill to Market: Opportunities for HIV and Pregnancy Prevention and Implications for Future MPTs

This video-recorded session from IAS 2021 examines opportunities for bringing the Dual Prevention Pill to market as well as implications for future multipurpose prevention technologies.

Should I Take PrEP? A mental models assessment of young African Women’s motivations for and barriers to PrEP initiation and adherence

Slide presentation exploring young African women's reasons for and against beginning to take PrEP and continuing to do so.

Research

Integrating STI Screening into PrEP Services for Adolescent Girls and Young Women in Two Primary Health Care Facilities in Inner-city Johannesburg: Lessons from prevention options for women evaluation research (POWER)

Slide presentation encouraging providers of PrEP to also discuss STI prevention.

Research, Service Delivery, Testing

Association Between Contraceptive Use and PrEP Uptake and Continuation in Adolescent Girls and Young Women in Cape Town, South Africa – INTEREST 2019

This presentation outlines the results from a study to determine the persistence and patterns of oral PrEP use in African young women.

Research, Service Delivery

PrEP Re-initiation After Interruption by Adolescent Girls and Young Women in Kenya and South Africa

Presentation made at AIS 2019 on evaluation of PrEP re-initiation after interruption amongst adolescent girls and young women in Kenya and South Africa

Research